Texas Permanent School Fund Corp Has $3.22 Million Position in Edwards Lifesciences Corporation $EW

Texas Permanent School Fund Corp lessened its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 35.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,223 shares of the medical research company’s stock after selling 22,542 shares during the period. Texas Permanent School Fund Corp’s holdings in Edwards Lifesciences were worth $3,224,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of EW. Brighton Jones LLC purchased a new position in Edwards Lifesciences during the 4th quarter valued at about $266,000. Aptus Capital Advisors LLC lifted its position in shares of Edwards Lifesciences by 3.8% in the first quarter. Aptus Capital Advisors LLC now owns 10,386 shares of the medical research company’s stock worth $753,000 after purchasing an additional 385 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Edwards Lifesciences during the first quarter worth approximately $26,000. Erste Asset Management GmbH grew its position in Edwards Lifesciences by 1.7% during the first quarter. Erste Asset Management GmbH now owns 19,820 shares of the medical research company’s stock valued at $1,405,000 after purchasing an additional 326 shares in the last quarter. Finally, CW Advisors LLC acquired a new position in Edwards Lifesciences in the 1st quarter valued at approximately $459,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on EW shares. Stifel Nicolaus set a $100.00 target price on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Friday, December 5th. UBS Group set a $92.00 price objective on Edwards Lifesciences in a research report on Friday, December 5th. National Bankshares set a $92.00 target price on Edwards Lifesciences in a research note on Friday, October 31st. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $90.00 price target on shares of Edwards Lifesciences in a research note on Monday, November 3rd. Finally, Oppenheimer lowered Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 8th. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $93.95.

Edwards Lifesciences Stock Performance

EW opened at $85.66 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. The company has a market cap of $49.71 billion, a PE ratio of 36.92, a price-to-earnings-growth ratio of 3.81 and a beta of 0.97. The stock has a 50-day moving average of $82.53 and a 200-day moving average of $79.27. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. The business had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The firm’s revenue was up 14.7% compared to the same quarter last year. During the same period last year, the business earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,700 shares of the company’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total transaction of $650,419.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at approximately $3,370,184.06. This represents a 16.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,386 shares of Edwards Lifesciences stock in a transaction on Friday, December 12th. The stock was sold at an average price of $83.76, for a total transaction of $953,691.36. Following the completion of the transaction, the vice president owned 38,970 shares in the company, valued at $3,264,127.20. This trade represents a 22.61% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 45,465 shares of company stock worth $3,804,610. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.